FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 30 of 40
Mar 30, 2026As we approach the second quarter of 2026, the Food and Drug Administration (FDA) has several high-profile decisions lined up that could significantly influence drug availability, market competition, and patient treatment options. These upcoming verdicts are particularly crucial in the areas of obesity management and other pressing health concerns.
Mar 30, 2026The approval of Kresladi represents a significant milestone in the treatment landscape for LAD-1, offering a pioneering therapeutic option for a condition with limited existing interventions. This development not only broadens treatment possibilities but also underscores the advancing role of gene therapy in addressing ultra-rare diseases.
Mar 27, 2026With healthcare costs under intense scrutiny, the White House has intensified its efforts to build bipartisan support for drug pricing reforms by engaging pharmaceutical companies through private discussions. These negotiations are part of a broader strategy to balance affordability with industry innovation incentives.
Mar 27, 2026The U.S. Food and Drug Administration has presented its current focal points to legislators, underscoring critical food safety issues and regulatory advances aimed at protecting public health. Key initiatives include enhanced oversight of infant formula, modernized labeling requirements, and stronger measures targeting processed food classifications.
Mar 27, 2026Robert Malone’s resignation from the vaccine committee has drawn attention to the internal dynamics between health committee members and government spokespersons. Malone cited his unwillingness to engage in drama as a key reason for stepping down, following public comments and disputes involving the Department of Health and Human Services.
Mar 27, 2026Rocket Pharma's Kresladi has secured FDA approval for the treatment of a rare immune disorder despite a limited clinical trial size. This approval underscores the ongoing evolution in gene therapy approaches and the regulatory acceptance of innovative treatments in rare disease spaces. The therapy's positive results in nine patients highlight the challenges and promises of addressing ultra-rare conditions.
Mar 26, 2026Denali Therapeutics’ recent FDA nod for Avlayah marks a pivotal moment in the treatment landscape of Hunter syndrome, a rare genetic disorder characterized by complex neurologic challenges. This approval underscores the FDA’s evolving approach to rare diseases and neuroscience-related conditions, offering new hope for patients and informing future drug development.
Mar 24, 2026The FDA's recent admonishment of prominent biotech figures over unsubstantiated claims highlights ongoing issues in maintaining scientific integrity and protecting patients. This article examines the regulatory intervention's background and broader implications for biotech communications.
Mar 24, 2026The drug price controls in Japan present complexities that complicate access, innovation, and international relations. Both Washington and Tokyo face obstacles that call for cooperative approaches to regulatory and economic reforms.
Mar 23, 2026Recent FDA findings highlight the emergence of seizure incidents associated with Parkinson’s drugs containing carbidopa/levodopa. The agency has reported cases linked to vitamin B6 deficiency, underscoring the need for heightened awareness among healthcare providers and patients alike.
Mar 23, 2026Since its unveiling in June 2025, the FDA’s Commissioner’s National Priority Voucher program has generated considerable discussion within regulatory and biopharmaceutical circles. The program is designed to incentivize drug development for critical areas, yet the lack of transparent criteria has left many uncertain about qualification and impact.
Mar 22, 2026The involvement of private equity firms in healthcare has been under increased scrutiny following a report by NYU Stern School of Business that links such investments to adverse effects on healthcare delivery and financial viability. The report advocates for reforms including stronger regulatory oversight to mitigate risks and improve outcomes for patients and providers alike.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.